Currently, immunotherapies targeting CTLA-4, PD-1, and PD-L1 are approved in a small number of indications, melanoma, bladder, NSCLC, and renal cell carcinoma. This evidence concerns the gene CTLA4 and hereditary clear cell renal cell carcinoma.